Mardia Samyoung Capillary Tubes Company share price today

Mardia Samyoung Capillary Tubes Company Ltd's share price was ₹51.94 at the close on 30 October 2026. It has been rising for 63 weeks. That is 5.1% below its average price over the last 200 trading days.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Mardia Samyoung Capillary Tubes Company Ltd is in stage 2. The phase helps read everything below.

In the last 52 weeks it traded between ₹41 and ₹123, and at that close it sat 14% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 8 weeks in a row.

Over the last 11 years the share price moved +366% while the NIFTY 500 moved +233%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

For October to December 2025 (the quarter ended 31 December 2025), Mardia Samyoung Capillary Tubes Company reported revenue of ₹12.3 crore, and a profit of ₹1.29 crore, against a loss of ₹0.05 crore a year earlier.

Mardia Samyoung Capillary Tubes Company results: October to December 2025 against a year earlier

The next results, for January to March 2026, were due by 30 May 2026: listed companies must publish quarterly results within 60 days of the quarter's end (the January to March quarter comes with the full-year accounts). This page shows them once our weekly data update has read them.

From the company's reported quarterly results (quarter ended 31 December 2025). Revenue and profit in ₹ crore.

Mardia Samyoung Capillary Tubes Company closed at ₹51.94 on 30 October 2026, down 54.5% from ₹114.08 a year earlier (31 October 2025). Its highest weekly close since April 2016 was ₹123.40 on 7 November 2025.

Mardia Samyoung Capillary Tubes Company share price: then and now

Weekly closing prices. Each change is the move from that price to the 30 Oct 2026 close. A day's intraday high or low can go beyond these weekly closes.

212 weekly closes from 5 April 2016 to 30 October 2026.

30 Oct 2026: Mardia Samyoung Capillary Tubes Company closed at ₹51.94, up 14.8% on the week and up 2.0% on the month.

Mardia Samyoung Capillary Tubes Company has paid no dividend on the NSE since 1 April 2021, the start of the period we checked.

No. Mardia Samyoung Capillary Tubes Company Ltd paid out 0% of its profit as dividends in each of its last 12 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the NSE corporate-actions record, read 5 November 2026.

Mardia Samyoung Capillary Tubes Company is not on any of our India lists this week.

Mardia Samyoung Capillary Tubes Company Ltd earned ₹1.3 Cr of net profit in the Dec 2025 quarter. Full-year FY25 profit was ₹1.2 Cr. That is 10.4% of the quarter's revenue. The same quarter a year earlier lost ₹0.1 Cr. 10 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Mardia Samyoung Capillary Tubes Company Ltd reported ₹12.3 Cr of revenue in the Dec 2025 quarter. The last full year, FY25, came in at ₹0.0 Cr. The last four reported quarters add to ₹12.8 Cr. A growth rate over several years is not shown, because there are too few years of figures to work one out properly.

Revenue is everything the company billed its customers in the period.

Mardia Samyoung Capillary Tubes Company Ltd's operating margin was 15.3% in the Dec 2025 quarter. Across 5 years it has been between −150.8% and 4,000.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why: the operating margin move is clear, but the cost details behind it are not in our data, so we show the move without guessing the reason.

Over the last 2 years Mardia Samyoung Capillary Tubes Company Ltd's operations used more cash than they brought in, so cash conversion was −206%, a gap worth watching. In FY25 its operations used ₹2.5 Cr of cash, against ₹1.2 Cr of profit. After −₹3.0 Cr of spending on assets, ₹0.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: it has been selling more assets than it buys. The next section shows those figures.

Mardia Samyoung Capillary Tubes Company Ltd's customer, stock and supplier day counts come out in the thousands of days on sales this small (₹0.0 Cr in FY25), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. Over the last 3 years it sold more assets than it bought, by ₹2.0 Cr.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Over the last 3 years, money from selling assets was ₹2.0 Cr more than it spent on new ones. Work still in progress is ₹0.0 Cr (FY25).

In short: assets are being sold, not built, so this cash is not going into new capacity.

Mardia Samyoung Capillary Tubes Company Ltd's P/E is 687.0×, with too little history to compare. Its usual P/E (the middle reading) is 307.0×, over 9.2 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple.

Mardia Samyoung Capillary Tubes Company Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 4 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Mardia Samyoung Capillary Tubes Company Ltd earned a ROCE of 23% in FY25. That is up from a low of −10% in FY24. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 364.3% net margin and −0.02× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY24): a 364.3% net margin × −0.02× asset turnover × 1.54× leverage (assets divided by equity) ≈ −11.2% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

Mardia Samyoung Capillary Tubes Company Ltd had ₹0.0 Cr of borrowings against ₹5.6 Cr of equity in FY25, so its debt is 0.00× its equity. Over 5 years borrowings went from ₹0.0 Cr to ₹0.0 Cr. Over the last 3 of those years it sold more assets than it bought, by ₹2.0 Cr.

Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.

The spending on assets is being paid for from cash, not new debt.

No group of Mardia Samyoung Capillary Tubes Company Ltd's owners changed its stake by a full percentage point over the last two years. Domestic institutions moved +0.0 points over the same period, to 0.1%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Promoters: +0.0 points over 8 quarters, to 69.4%; Domestic institutions: +0.0 points over 8 quarters, to 0.1%.

For Mardia Samyoung Capillary Tubes Company Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

55.3 out of 100, rank 52 of 63 in Trading, with 26% of the evidence available. It is provisional, so it is ranked below companies with full evidence.

Mardia Samyoung Capillary Tubes Company Ltd scores 55.3 out of 100 against the 63 companies it is compared with in Trading, ranking 52. Some evidence is missing, so the score is pulled toward the middle on purpose.

The three scored parts add up to the total exactly: 25.4 + 19.1 + 10.8 = 55.3 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Mardia Samyoung Capillary Tubes Company ranks 52 of 63 Trading companies on the 4-Factor Sector Score, with 55.3 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Trading, all 63 compared on one page.

Mardia Samyoung Capillary Tubes Company is the 32nd largest of 59 Trading companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Shiv Aum Steels, Prostarm Info Systems and Maxgrow India. Just below it: Yogi, Proventus Agrocom and Neueon Corporation.

Trading companies close in size

29. Shiv Aum Steels Ltd ₹742 crore
30. Prostarm Info Systems Ltd ₹735 crore
31. Maxgrow India Ltd ₹709 crore
32. Mardia Samyoung Capillary Tubes Company Ltd ₹707 crore
33. Yogi Ltd ₹688 crore
34. Proventus Agrocom Ltd ₹670 crore
35. Neueon Corporation Ltd ₹615 crore

All 59 Trading companies, largest first

Companies close in size in other industries

2144. Globe International Carriers Ltd ₹421 crore · Transport - Road
2145. Magnus Steel & Infra Ltd ₹417 crore · Trading
2146. Mardia Samyoung Capillary Tubes Company Ltd ₹413 crore
2147. Plastiblends India Ltd ₹413 crore · Plastics - Plastic & Plastic Products
2148. Forbes & Company Ltd ₹412 crore

Sector Alpha, written by code from the published numbers. Data as of 30 October 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.